The global urinalysis market was valued at $3.9 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2022 to 2027 to reach $5.7 billion, according to a new report from MarketsandMarkets. Growth is being driven by factors like the increased focus on disease screening by governments, high prevalence of lifestyle diseases like diabetes and kidney disease, and greater awareness initiatives around these conditions.
Request for Free Sample Report
The largest product segment is consumables, which account for the majority of the total market value. This includes items like dipsticks, pregnancy test kits, reagents, and disposables. This segment is seeing rising investments in new diagnostic product development as well as increasing demand for rapid disease diagnosis.
By test type, pregnancy and fertility tests make up the greatest portion of the urinalysis industry currently. This segment is expanding thanks to technological advancements leading to more advanced at-home pregnancy and ovulation test kit products.
In terms of application, disease screening makes up the largest share at present. Key drivers here are the aging population leading to more age-related illnesses, emerging economies providing growth opportunities, and greater adoption of point-of-care testing which frequently utilizes urinalysis for quick results.
Diagnostic laboratories dominate the end-user segment for urinalysis. Supporting factors include growing age-related conditions, more point-of-care analyzer usage, and favorable regulatory and reimbursement scenarios in developed regions like North America and Europe.
Geographically, North America holds the largest piece of the global urinalysis market presently. Rising rates of diseases like diabetes and UTIs, supportive governmental policies, and robust investment into diagnostic test development and approvals for preventative care are spurring the North American market higher.
Some recent notable developments in the competitive landscape include:
- Sysmex launching an automated particle urine analyzer called the UF-1500 for sediment testing in September 2022
- Thermo Fisher Scientific and Mindray signing a deal in February 2021 to provide toxicology labs with Mindray’s BS-480 and BA-800M UA analyzers
- An exclusive agreement announced in August 2020 between Sysmex America and Siemens Healthineers
Key players operating in the global urinalysis space include major companies like:
- Siemens Healthineers
- Roche
- Cardinal Health
- Abbott Laboratories
- Danaher Corporation
- Sysmex Corporation
- Quidel Corporation
- Bio-Rad Laboratories
- EKF Diagnostics
- Thermo Fisher Scientific
- ARKRAY
- ACON Laboratories
There remain opportunities for innovation and growth within the urinalysis products market in areas like:
- Developing automated, high-throughput urine analysis systems to handle more samples faster
- Expanding point-of-care urine testing for quicker results in clinical settings
- Leveraging emerging market demand as healthcare infrastructure modernizes
Request for Free Sample Report
In summary, the global market for urinalysis products, services, and equipment shows positive future expansion potential supported by trends like greater focus on preventative screening, technology advancements towards automation, and rising rates of target diseases like diabetes amongst aging populations in developing and developed regions. Key players are making strategic moves to capitalize on opportunities through innovative product development and regional distribution deals.